Alibaba (BABA) Reaches $600M DOJ Settlement Following Illegal Drug Sales Investigation

Key Takeaways

• The Chinese e-commerce giant and AUS Merchant Services will pay a combined $600 million to settle Department of Justice charges
• Federal authorities identified approximately 80,000 unlawful transactions involving pharmaceuticals and chemical substances from 2016 through 2024, representing more than $200 million in total value
• The settlement requires Alibaba to surrender $200 million plus a $125 million fine; AUS must pay $85 million in fines and forfeit $190 million
• The agreement includes non-prosecution terms with mandatory compliance improvements
• Federal investigators conducted over 40 test purchases of prohibited drugs and counterfeiting tools through the platform

Shares of Alibaba advanced 1.78% on Wednesday following the announcement of a $600 million agreement with federal prosecutors to resolve allegations concerning illegal pharmaceutical transactions on its e-commerce platform.

Alibaba Group Holding Limited, BABA

The settlement encompasses both Alibaba and AUS Merchant Services, its American payment processing subsidiary.

Under the terms, neither entity will face criminal prosecution. However, both organizations acknowledged their failures and committed to comprehensive compliance reforms.

According to federal prosecutors, Alibaba’s platform facilitated approximately 80,000 illegal sales involving prescription medications, precursor chemicals, and pill manufacturing equipment over an eight-year period ending in 2024.

The total gross merchandise value of these prohibited transactions exceeded $200 million.

Under the settlement terms, Alibaba must surrender $200 million in forfeiture and pay an additional $125 million criminal fine.

Meanwhile, AUS Merchant Services faces $85 million in penalties and must forfeit $190 million, totaling the $600 million settlement amount.

Federal agents working undercover successfully purchased illegal pharmaceuticals and equipment for manufacturing counterfeit pills more than 40 times directly from sellers on Alibaba’s marketplace.

Prosecutors revealed that several Alibaba staff members had raised internal questions about whether existing compliance protocols were sufficient to prevent illicit transactions. These warnings went largely unheeded.

The company also maintained a private messaging feature that certain sellers exploited to conduct prohibited sales away from standard oversight mechanisms.

Payment Processor Compliance Failures

AUS Merchant Services acknowledged its anti-money laundering systems and transaction oversight were inadequate to detect criminal activity.

Despite identifying sellers engaged in prohibited commerce, AUS failed to suspend their payment privileges and simply directed them back to Alibaba. At minimum one merchant continued illegal operations following initial detection.

Settlement Stipulations

“Alibaba and AUS have documented steps taken to improve their screening and compliance and provided a commitment to ongoing cooperation with US law enforcement in the future,” said Assistant Attorney General Tysen Duva.

Both organizations must maintain active cooperation with federal authorities and implement enhanced compliance systems moving forward.

Alibaba characterized the resolution as a “mutually satisfactory” outcome and emphasized its “full cooperation” during the investigative process.

Assistant AG Brett Shumate added: “Today’s resolution reflects the Department of Justice’s commitment to ensuring that companies operating e-commerce and digital payment platforms keep illegal, unapproved, misbranded, and dangerous foreign pharmaceuticals off their marketplaces.”

The violations addressed in this settlement involve breaches of the Federal Food, Drug, and Cosmetic Act.